查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1423778

進行性多灶性白質腦病變治療的全球市場-全球產業分析、規模、份額、成長、趨勢、預測(2031)-藥物類型、適應症、分銷管道、地區

Progressive Multifocal Leukoencephalopathy Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region:
出版日期: | 出版商: Fairfield Market Research | 英文 208 Pages | 商品交期: 2-5個工作天內

價格
簡介目錄

預計 2024 年至 2031 年，進行性多灶性白質腦病變治療的全球市場規模將穩定成長。 許多低收入和中等收入國家的愛滋病毒感染率不斷上升，預計將增加對進行性多灶性白質腦病變治療的需求。 血液惡性腫瘤盛行率的增加和進行性多灶性白質腦病變的診斷正在推動市場擴張。 愛滋病毒和癌症治療的有利報銷政策預計將刺激進行性多灶性白質腦病變治療市場的成長。 包括抗逆轉錄病毒和抗病毒療法在內的新治療方案的引入，正在為市場新進入者創造利潤豐厚的機會。 HIV 和進行性多灶性白質腦病的檢測、診斷和治療方面的進步，以及醫療設施和政府計畫的改進，正在推動市場成長。

在 HIV 感染、血液惡性腫瘤和進行性多灶性白質腦病患病率上升的推動下，北美和歐洲預計將引領進行性多灶性白質腦病變治療市場。 由於愛滋病毒感染率上升、愛滋病毒和癌症治療率提高以及對進行性多灶性白質腦病變的認識提高，亞太市場預計將持續成長。 在低收入和中等收入經濟體中，增加治療的□□使用、獲得安全有效的治療以及準確的癌症診斷可能有助於增加進行性多灶性白質腦病變的診斷。

本報告調查了全球進行性多灶性白質腦病治療市場，提供了市場概述、按藥物類型、適應症、分銷渠道、地區和進入市場的公司劃分的趨勢。提供了競爭趨勢等資訊。

目錄

第 1 章執行摘要

第 2 章市場概述

  • 市場定義與細分
  • 市場動態
  • 價值鏈分析
  • 波特五力分析
  • 新冠肺炎 (COVID-19) 影響分析
  • 烏克蘭和俄羅斯之間衝突的影響
  • 經濟概況
  • PESTLE分析

第 3 章2018-2031 年全球進行性多灶性白質腦病變治療市場前景

  • 2018-2031 年全球進行性多灶性白質腦病變治療市場前景，按藥物類型、價值（十億美元））
  • 2018-2031 年全球進行性多灶性白質腦病變治療市場前景，按適應症、價值（十億美元））
  • 2018-2031 年全球漸進式多灶性白質腦病變治療市場展望，按分銷管道劃分，價值（十億美元）
  • 2018-2031 年全球漸進式多灶性白質腦病變治療市場前景，按地區、價值（十億美元））

第 4 章2018-2031 年北美進行性多灶性白質腦病變治療市場前景

第 5 章歐洲進行性多灶性白質腦病變治療市場前景，2018-2031

第 6 章2018-2031 年亞太地區進行性多灶性白質腦病變治療市場前景

第 7 章拉丁美洲漸進式多灶性白質腦病變治療市場展望，2018-2031 年

第 8 章中東與非洲漸進式多灶性白質腦病變治療市場展望，2018-2031 年

第 9 章競爭態勢

  • 藥品類型與通路熱圖
  • 製造商和分銷通路熱圖
  • 2023 年公司市佔率分析
  • 競爭對手儀表板
  • 公司簡介
    • Pfizer, Inc.
    • F. Hoffman - La Roche Ltd.
    • Gilead Sciences, Inc.
    • GlaxoSmithKline plc
    • Sanofi S.A.
    • Allergan plc
    • Novartis AG
    • Mylan N.V.
    • AbbVie Inc.
    • Bristol-Myers Squibb Company

第 10 章附錄

簡介目錄

The global progressive multifocal leukoencephalopathy treatment market is set to experience steady growth from 2024 to 2031. Several key insights are driving this growth in the market:

Factors Driving Market Growth:

  • Rising HIV Prevalence: The growing prevalence of HIV infection in many middle- and low-income countries is expected to fuel the demand for progressive multifocal leukoencephalopathy treatment.
  • Hematological Malignancies: An increasing incidence of hematological malignancies and the diagnosis of progressive multifocal leukoencephalopathy are driving the market's expansion.
  • Favorable Reimbursements: Favorable reimbursement policies for HIV and cancer treatments are expected to stimulate growth in the progressive multifocal leukoencephalopathy treatment market.
  • Emerging Treatment Options: The introduction of emerging treatment options, including anti-retroviral and antiviral therapies, is creating lucrative opportunities for new entrants in the market.
  • Healthcare Infrastructure Improvement: Advances in HIV and progressive multifocal leukoencephalopathy testing, diagnosis, and treatment, along with improved healthcare facilities and government programs, are boosting market growth.

Regional Outlook:

  • North America: North America, followed by Europe, is anticipated to lead the progressive multifocal leukoencephalopathy treatment market, driven by the increasing prevalence of HIV infection, hematological malignancies, and progressive multifocal leukoencephalopathy.
  • Asia-Pacific: The Asia-Pacific market is expected to witness continuous growth due to the rising HIV infection rates, improving treatment rates for HIV and cancer, and increasing awareness about progressive multifocal leukoencephalopathy.
  • Middle East & Africa: Growing treatment-seeking rates in middle- and low-income economies, along with access to safe and effective treatment and accurate cancer diagnosis, will likely contribute to increased progressive multifocal leukoencephalopathy diagnoses.

Opportunities for Growth:

  • Antiviral Agents: The use of antiviral agents, immune response modulators, and immunization treatment for potential progressive multifocal leukoencephalopathy patients is expected to drive market growth.
  • Research and Development: Emphasis on researching and developing drugs and therapies for rare diseases presents a significant opportunity for the progressive multifocal leukoencephalopathy treatment market.
  • Innovative Therapies: Companies are exploring innovative therapies to control JC virus infection rather than improving immunity, which is likely to spur market growth.
  • Improvement in Available Treatments: Leading companies in the progressive multifocal leukoencephalopathy treatment market are focusing on enhancing available treatment options.

Key Players:

Some of the key players in the global progressive multifocal leukoencephalopathy treatment market include Pfizer, Inc., GlaxoSmithKline Plc, Sanofi S.A., Gilead Sciences, Inc., Allergan Plc. (Actavis Plc.), Novartis AG, F. Hoffman - La Roche Ltd., AbbVie Inc., and Bristol-Myers Squibb Company, among others.

Table of Contents

1. Executive Summary

  • 1.1. Global Progressive Multifocal Leukoencephalopathy Treatment Market Snapshot
  • 1.2. Future Projections
  • 1.3. Key Market Trends
  • 1.4. Regional Snapshot, by Value, 2023
  • 1.5. Analyst Recommendations

2. Market Overview

  • 2.1. Market Definitions and Segmentations
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Market Opportunities
  • 2.3. Value Chain Analysis
  • 2.4. Porter's Five Forces Analysis
  • 2.5. COVID-19 Impact Analysis
    • 2.5.1. Supply
    • 2.5.2. Demand
  • 2.6. Impact of Ukraine-Russia Conflict
  • 2.7. Economic Overview
    • 2.7.1. World Economic Projections
  • 2.8. PESTLE Analysis

3. Global Progressive Multifocal Leukoencephalopathy Treatment Market Outlook, 2018 - 2031

  • 3.1. Global Progressive Multifocal Leukoencephalopathy Treatment Market Outlook, by Drug Type, Value (US$ Bn), 2018 - 2031
    • 3.1.1. Key Highlights
      • 3.1.1.1. Anti-retroviral Therapy
      • 3.1.1.2. Antiviral/Anti JCV
      • 3.1.1.3. Other Symptomatic
  • 3.2. Global Progressive Multifocal Leukoencephalopathy Treatment Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
    • 3.2.1. Key Highlights
      • 3.2.1.1. HIV/AIDS
      • 3.2.1.2. Organ Transplantation
      • 3.2.1.3. Multiple Sclerosis
      • 3.2.1.4. Hematological Malignancies
  • 3.3. Global Progressive Multifocal Leukoencephalopathy Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 3.3.1. Key Highlights
      • 3.3.1.1. Hospital Pharmacies
      • 3.3.1.2. Drug Stores
      • 3.3.1.3. Retail Pharmacies
  • 3.4. Global Progressive Multifocal Leukoencephalopathy Treatment Market Outlook, by Region, Value (US$ Bn), 2018 - 2031
    • 3.4.1. Key Highlights
      • 3.4.1.1. North America
      • 3.4.1.2. Europe
      • 3.4.1.3. Asia Pacific
      • 3.4.1.4. Latin America
      • 3.4.1.5. Middle East & Africa

4. North America Progressive Multifocal Leukoencephalopathy Treatment Market Outlook, 2018 - 2031

  • 4.1. North America Progressive Multifocal Leukoencephalopathy Treatment Market Outlook, by Drug Type, Value (US$ Bn), 2018 - 2031
    • 4.1.1. Key Highlights
      • 4.1.1.1. Anti-retroviral Therapy
      • 4.1.1.2. Antiviral/Anti JCV
      • 4.1.1.3. Other Symptomatic
  • 4.2. North America Progressive Multifocal Leukoencephalopathy Treatment Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
    • 4.2.1. Key Highlights
      • 4.2.1.1. HIV/AIDS
      • 4.2.1.2. Organ Transplantation
      • 4.2.1.3. Multiple Sclerosis
      • 4.2.1.4. Hematological Malignancies
  • 4.3. North America Progressive Multifocal Leukoencephalopathy Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 4.3.1. Key Highlights
      • 4.3.1.1. Hospital Pharmacies
      • 4.3.1.2. Drug Stores
      • 4.3.1.3. Retail Pharmacies
  • 4.4. North America Progressive Multifocal Leukoencephalopathy Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 4.4.1. Key Highlights
      • 4.4.1.1. U.S. Progressive Multifocal Leukoencephalopathy Treatment Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 4.4.1.2. U.S. Progressive Multifocal Leukoencephalopathy Treatment Market by Indication, Value (US$ Bn), 2018 - 2031
      • 4.4.1.3. U.S. Progressive Multifocal Leukoencephalopathy Treatment Market Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 4.4.1.4. Canada Progressive Multifocal Leukoencephalopathy Treatment Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 4.4.1.5. Canada Progressive Multifocal Leukoencephalopathy Treatment Market by Indication, Value (US$ Bn), 2018 - 2031
      • 4.4.1.6. Canada Progressive Multifocal Leukoencephalopathy Treatment Market Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 4.4.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Progressive Multifocal Leukoencephalopathy Treatment Market Outlook, 2018 - 2031

  • 5.1. Europe Progressive Multifocal Leukoencephalopathy Treatment Market Outlook, by Drug Type, Value (US$ Bn), 2018 - 2031
    • 5.1.1. Key Highlights
      • 5.1.1.1. Anti-retroviral Therapy
      • 5.1.1.2. Antiviral/Anti JCV
      • 5.1.1.3. Other Symptomatic
  • 5.2. Europe Progressive Multifocal Leukoencephalopathy Treatment Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
    • 5.2.1. Key Highlights
      • 5.2.1.1. HIV/AIDS
      • 5.2.1.2. Organ Transplantation
      • 5.2.1.3. Multiple Sclerosis
      • 5.2.1.4. Hematological Malignancies
  • 5.3. Europe Progressive Multifocal Leukoencephalopathy Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 5.3.1. Key Highlights
      • 5.3.1.1. Hospital Pharmacies
      • 5.3.1.2. Drug Stores
      • 5.3.1.3. Retail Pharmacies
  • 5.4. Europe Progressive Multifocal Leukoencephalopathy Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 5.4.1. Key Highlights
      • 5.4.1.1. Germany Progressive Multifocal Leukoencephalopathy Treatment Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 5.4.1.2. Germany Progressive Multifocal Leukoencephalopathy Treatment Market by Indication, Value (US$ Bn), 2018 - 2031
      • 5.4.1.3. Germany Progressive Multifocal Leukoencephalopathy Treatment Market Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 5.4.1.4. U.K. Progressive Multifocal Leukoencephalopathy Treatment Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 5.4.1.5. U.K. Progressive Multifocal Leukoencephalopathy Treatment Market by Indication, Value (US$ Bn), 2018 - 2031
      • 5.4.1.6. U.K. Progressive Multifocal Leukoencephalopathy Treatment Market Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 5.4.1.7. France Progressive Multifocal Leukoencephalopathy Treatment Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 5.4.1.8. France Progressive Multifocal Leukoencephalopathy Treatment Market by Indication, Value (US$ Bn), 2018 - 2031
      • 5.4.1.9. France Progressive Multifocal Leukoencephalopathy Treatment Market Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 5.4.1.10. Italy Progressive Multifocal Leukoencephalopathy Treatment Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 5.4.1.11. Italy Progressive Multifocal Leukoencephalopathy Treatment Market by Indication, Value (US$ Bn), 2018 - 2031
      • 5.4.1.12. Italy Progressive Multifocal Leukoencephalopathy Treatment Market Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 5.4.1.13. Turkey Progressive Multifocal Leukoencephalopathy Treatment Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 5.4.1.14. Turkey Progressive Multifocal Leukoencephalopathy Treatment Market by Indication, Value (US$ Bn), 2018 - 2031
      • 5.4.1.15. Turkey Progressive Multifocal Leukoencephalopathy Treatment Market Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 5.4.1.16. Russia Progressive Multifocal Leukoencephalopathy Treatment Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 5.4.1.17. Russia Progressive Multifocal Leukoencephalopathy Treatment Market by Indication, Value (US$ Bn), 2018 - 2031
      • 5.4.1.18. Russia Progressive Multifocal Leukoencephalopathy Treatment Market Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 5.4.1.19. Rest of Europe Progressive Multifocal Leukoencephalopathy Treatment Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 5.4.1.20. Rest of Europe Progressive Multifocal Leukoencephalopathy Treatment Market by Indication, Value (US$ Bn), 2018 - 2031
      • 5.4.1.21. Rest of Europe Progressive Multifocal Leukoencephalopathy Treatment Market Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 5.4.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Progressive Multifocal Leukoencephalopathy Treatment Market Outlook, 2018 - 2031

  • 6.1. Asia Pacific Progressive Multifocal Leukoencephalopathy Treatment Market Outlook, by Drug Type, Value (US$ Bn), 2018 - 2031
    • 6.1.1. Key Highlights
      • 6.1.1.1. Anti-retroviral Therapy
      • 6.1.1.2. Antiviral/Anti JCV
      • 6.1.1.3. Other Symptomatic
  • 6.2. Asia Pacific Progressive Multifocal Leukoencephalopathy Treatment Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
    • 6.2.1. Key Highlights
      • 6.2.1.1. HIV/AIDS
      • 6.2.1.2. Organ Transplantation
      • 6.2.1.3. Multiple Sclerosis
      • 6.2.1.4. Hematological Malignancies
  • 6.3. Asia Pacific Progressive Multifocal Leukoencephalopathy Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 6.3.1. Key Highlights
      • 6.3.1.1. Hospital Pharmacies
      • 6.3.1.2. Drug Stores
      • 6.3.1.3. Retail Pharmacies
  • 6.4. Asia Pacific Progressive Multifocal Leukoencephalopathy Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 6.4.1. Key Highlights
      • 6.4.1.1. China Progressive Multifocal Leukoencephalopathy Treatment Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 6.4.1.2. China Progressive Multifocal Leukoencephalopathy Treatment Market by Indication, Value (US$ Bn), 2018 - 2031
      • 6.4.1.3. China Progressive Multifocal Leukoencephalopathy Treatment Market Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 6.4.1.4. Japan Progressive Multifocal Leukoencephalopathy Treatment Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 6.4.1.5. Japan Progressive Multifocal Leukoencephalopathy Treatment Market by Indication, Value (US$ Bn), 2018 - 2031
      • 6.4.1.6. Japan Progressive Multifocal Leukoencephalopathy Treatment Market Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 6.4.1.7. South Korea Progressive Multifocal Leukoencephalopathy Treatment Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 6.4.1.8. South Korea Progressive Multifocal Leukoencephalopathy Treatment Market by Indication, Value (US$ Bn), 2018 - 2031
      • 6.4.1.9. South Korea Progressive Multifocal Leukoencephalopathy Treatment Market Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 6.4.1.10. India Progressive Multifocal Leukoencephalopathy Treatment Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 6.4.1.11. India Progressive Multifocal Leukoencephalopathy Treatment Market by Indication, Value (US$ Bn), 2018 - 2031
      • 6.4.1.12. India Progressive Multifocal Leukoencephalopathy Treatment Market Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 6.4.1.13. Southeast Asia Progressive Multifocal Leukoencephalopathy Treatment Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 6.4.1.14. Southeast Asia Progressive Multifocal Leukoencephalopathy Treatment Market by Indication, Value (US$ Bn), 2018 - 2031
      • 6.4.1.15. Southeast Asia Progressive Multifocal Leukoencephalopathy Treatment Market Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 6.4.1.16. Rest of Asia Pacific Progressive Multifocal Leukoencephalopathy Treatment Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 6.4.1.17. Rest of Asia Pacific Progressive Multifocal Leukoencephalopathy Treatment Market by Indication, Value (US$ Bn), 2018 - 2031
      • 6.4.1.18. Rest of Asia Pacific Progressive Multifocal Leukoencephalopathy Treatment Market Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 6.4.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Progressive Multifocal Leukoencephalopathy Treatment Market Outlook, 2018 - 2031

  • 7.1. Latin America Progressive Multifocal Leukoencephalopathy Treatment Market Outlook, by Drug Type, Value (US$ Bn), 2018 - 2031
    • 7.1.1. Key Highlights
      • 7.1.1.1. Anti-retroviral Therapy
      • 7.1.1.2. Antiviral/Anti JCV
      • 7.1.1.3. Other Symptomatic
  • 7.2. Latin America Progressive Multifocal Leukoencephalopathy Treatment Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
    • 7.2.1. Key Highlights
      • 7.2.1.1. HIV/AIDS
      • 7.2.1.2. Organ Transplantation
      • 7.2.1.3. Multiple Sclerosis
      • 7.2.1.4. Hematological Malignancies
  • 7.3. Latin America Progressive Multifocal Leukoencephalopathy Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 7.3.1. Key Highlights
      • 7.3.1.1. Hospital Pharmacies
      • 7.3.1.2. Drug Stores
      • 7.3.1.3. Retail Pharmacies
  • 7.4. Latin America Progressive Multifocal Leukoencephalopathy Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 7.4.1. Key Highlights
      • 7.4.1.1. Brazil Progressive Multifocal Leukoencephalopathy Treatment Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 7.4.1.2. Brazil Progressive Multifocal Leukoencephalopathy Treatment Market by Indication, Value (US$ Bn), 2018 - 2031
      • 7.4.1.3. Brazil Progressive Multifocal Leukoencephalopathy Treatment Market Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 7.4.1.4. Mexico Progressive Multifocal Leukoencephalopathy Treatment Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 7.4.1.5. Mexico Progressive Multifocal Leukoencephalopathy Treatment Market by Indication, Value (US$ Bn), 2018 - 2031
      • 7.4.1.6. Mexico Progressive Multifocal Leukoencephalopathy Treatment Market Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 7.4.1.7. Argentina Progressive Multifocal Leukoencephalopathy Treatment Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 7.4.1.8. Argentina Progressive Multifocal Leukoencephalopathy Treatment Market by Indication, Value (US$ Bn), 2018 - 2031
      • 7.4.1.9. Argentina Progressive Multifocal Leukoencephalopathy Treatment Market Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 7.4.1.10. Rest of Latin America Progressive Multifocal Leukoencephalopathy Treatment Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 7.4.1.11. Rest of Latin America Progressive Multifocal Leukoencephalopathy Treatment Market by Indication, Value (US$ Bn), 2018 - 2031
      • 7.4.1.12. Rest of Latin America Progressive Multifocal Leukoencephalopathy Treatment Market Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 7.4.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Progressive Multifocal Leukoencephalopathy Treatment Market Outlook, 2018 - 2031

  • 8.1. Middle East & Africa Progressive Multifocal Leukoencephalopathy Treatment Market Outlook, by Drug Type, Value (US$ Bn), 2018 - 2031
    • 8.1.1. Key Highlights
      • 8.1.1.1. Anti-retroviral Therapy
      • 8.1.1.2. Antiviral/Anti JCV
      • 8.1.1.3. Other Symptomatic
  • 8.2. Middle East & Africa Progressive Multifocal Leukoencephalopathy Treatment Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
    • 8.2.1. Key Highlights
      • 8.2.1.1. HIV/AIDS
      • 8.2.1.2. Organ Transplantation
      • 8.2.1.3. Multiple Sclerosis
      • 8.2.1.4. Hematological Malignancies
  • 8.3. Middle East & Africa Progressive Multifocal Leukoencephalopathy Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 8.3.1. Key Highlights
      • 8.3.1.1. Hospital Pharmacies
      • 8.3.1.2. Drug Stores
      • 8.3.1.3. Retail Pharmacies
  • 8.4. Middle East & Africa Progressive Multifocal Leukoencephalopathy Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 8.4.1. Key Highlights
      • 8.4.1.1. GCC Progressive Multifocal Leukoencephalopathy Treatment Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 8.4.1.2. GCC Progressive Multifocal Leukoencephalopathy Treatment Market by Indication, Value (US$ Bn), 2018 - 2031
      • 8.4.1.3. GCC Progressive Multifocal Leukoencephalopathy Treatment Market Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 8.4.1.4. South Africa Progressive Multifocal Leukoencephalopathy Treatment Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 8.4.1.5. South Africa Progressive Multifocal Leukoencephalopathy Treatment Market by Indication, Value (US$ Bn), 2018 - 2031
      • 8.4.1.6. South Africa Progressive Multifocal Leukoencephalopathy Treatment Market Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 8.4.1.7. Egypt Progressive Multifocal Leukoencephalopathy Treatment Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 8.4.1.8. Egypt Progressive Multifocal Leukoencephalopathy Treatment Market by Indication, Value (US$ Bn), 2018 - 2031
      • 8.4.1.9. Egypt Progressive Multifocal Leukoencephalopathy Treatment Market Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 8.4.1.10. Nigeria Progressive Multifocal Leukoencephalopathy Treatment Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 8.4.1.11. Nigeria Progressive Multifocal Leukoencephalopathy Treatment Market by Indication, Value (US$ Bn), 2018 - 2031
      • 8.4.1.12. Nigeria Progressive Multifocal Leukoencephalopathy Treatment Market Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 8.4.1.13. Rest of Middle East & Africa Progressive Multifocal Leukoencephalopathy Treatment Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 8.4.1.14. Rest of Middle East & Africa Progressive Multifocal Leukoencephalopathy Treatment Market by Indication, Value (US$ Bn), 2018 - 2031
      • 8.4.1.15. Rest of Middle East & Africa Progressive Multifocal Leukoencephalopathy Treatment Market Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 8.4.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

  • 9.1. Drug Type vs Distribution Channel Heatmap
  • 9.2. Manufacturer vs Distribution Channel Heatmap
  • 9.3. Company Market Share Analysis, 2023
  • 9.4. Competitive Dashboard
  • 9.5. Company Profiles
    • 9.5.1. Pfizer, Inc.
      • 9.5.1.1. Company Overview
      • 9.5.1.2. Drug Type Portfolio
      • 9.5.1.3. Financial Overview
      • 9.5.1.4. Business Strategies and Development
    • 9.5.2. F. Hoffman - La Roche Ltd.
      • 9.5.2.1. Company Overview
      • 9.5.2.2. Drug Type Portfolio
      • 9.5.2.3. Financial Overview
      • 9.5.2.4. Business Strategies and Development
    • 9.5.3. Gilead Sciences, Inc.
      • 9.5.3.1. Company Overview
      • 9.5.3.2. Drug Type Portfolio
      • 9.5.3.3. Financial Overview
      • 9.5.3.4. Business Strategies and Development
    • 9.5.4. GlaxoSmithKline plc
      • 9.5.4.1. Company Overview
      • 9.5.4.2. Drug Type Portfolio
      • 9.5.4.3. Financial Overview
      • 9.5.4.4. Business Strategies and Development
    • 9.5.5. Sanofi S.A.
      • 9.5.5.1. Company Overview
      • 9.5.5.2. Drug Type Portfolio
      • 9.5.5.3. Financial Overview
      • 9.5.5.4. Business Strategies and Development
    • 9.5.6. Allergan plc
      • 9.5.6.1. Company Overview
      • 9.5.6.2. Drug Type Portfolio
      • 9.5.6.3. Financial Overview
      • 9.5.6.4. Business Strategies and Development
    • 9.5.7. Novartis AG
      • 9.5.7.1. Company Overview
      • 9.5.7.2. Drug Type Portfolio
      • 9.5.7.3. Financial Overview
      • 9.5.7.4. Business Strategies and Development
    • 9.5.8. Mylan N.V.
      • 9.5.8.1. Company Overview
      • 9.5.8.2. Drug Type Portfolio
      • 9.5.8.3. Financial Overview
      • 9.5.8.4. Business Strategies and Development
    • 9.5.9. AbbVie Inc.
      • 9.5.9.1. Company Overview
      • 9.5.9.2. Drug Type Portfolio
      • 9.5.9.3. Financial Overview
      • 9.5.9.4. Business Strategies and Development
    • 9.5.10. Bristol-Myers Squibb Company
      • 9.5.10.1. Company Overview
      • 9.5.10.2. Drug Type Portfolio
      • 9.5.10.3. Financial Overview
      • 9.5.10.4. Business Strategies and Development

10. Appendix

  • 10.1. Research Methodology
  • 10.2. Report Assumptions
  • 10.3. Acronyms and Abbreviations